Tag Archives: Investment

Investment Pros Remain Bullish on Orphans

 An illustrious panel of investment professionals spoke optimistically on the orphan disease space in spite of concerns surrounding escalating drug prices in specialty pharmaceuticals. The group consisting of executives from investment banks, hedge funds, venture capital firms and biopharma companies spoke to the National Organization for Rare Disease (NORD) at its s Rare Diseases and […]
Posted in Orphan Drugs, pricing | Also tagged , | Leave a comment

The Transatlantic Trade and Investment Partnership: From Hot TTIP to Oblivion?

Only a year ago, hopes were high of rapid progress towards a transatlantic trade deal that would boost the European and US economies — and ease conditions for drug firms on both sides of the ocean. TTIP, the Transatlantic Trade and Investment Partnership, was the hot tip for a 2014 success story. But as summer […]
Posted in Europe, Global | Also tagged , , , , | Leave a comment

Pharma Manufacturing Investments Reflect Key Industry Trends

Shrinking facility size, growth of biologics, and emerging market demand influence pharma investments. Pharmaceutical Technology’s Cynthia Challener offers summary of selected investments in both small- and large-molecule manufacturing facilities during the last year. Numerous trends in the pharmaceutical industry, and particularly in the biopharmaceutical sector, are leading to the need for smaller-capacity production facilities, which in […]
Posted in Manufacturing | Also tagged , , , | Leave a comment

Biopharma Innovation in Trouble?

Next year it will cost $2.2 million to submit an NDA or biologics license application (BLA) for FDA review, and $1 million for a supplement with clinical data, generally to support new indications or expanded labeling. Review of a new biosimilar application that carries clinical data will be just as costly. While a $2 million […]
Posted in Biotech, FDA, Guest Blog | Also tagged , , , | Leave a comment

Into the Extrapolation Machine: How We Joined the Elite 58%

By Les Funtleyder. The problem we see with the polarity of views is that both sides seem to be cranking up the extrapolation machine and use single studies/data points to draw broad conclusions to gin up opinions about ACA’s success or lack thereof. With respect to investing, uncertainly caused by media/pundit noise often depresses valuations […]
Posted in Guest Blog, healthcare, Op-Ed | Also tagged , , , , , , , , , | Leave a comment
  • Categories

  • Meta